ZEJULA

Peak

niraparib tosylate

NDAORALCAPSULEPriority Review

Approved

Mar 2017

Lifecycle

Peak

Competitive Pressure

0/100

Clinical Trials

1

Clinical Trials (1)

NCT06237205Phase 2Not Yet Recruiting

Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency

Started Feb 2024

33 enrolled

Efficacy

Loss of Exclusivity

LOE Date

Mar 27, 2038

146 months away

Patent Expiry

Mar 27, 2038

Exclusivity Expiry

Apr 29, 2027

Patent Records (5)

Patent #	Expiry	Type	Use Code
8143241	Aug 12, 2027		U-2655
8071579	Aug 12, 2027		U-2655
8436185	Apr 24, 2029	Substance	—
8071623	Mar 27, 2031	SubstanceProduct	—
8859562	Aug 4, 2031		U-2655

Company

LONDON, United Kingdom

External Resources

FDA approval history

Drug nomenclature & identifiers